WC Magazine: Putting Out Fires

March 19, 2018

StateWatch: Early Spring 2018

March 19, 2018

The FDA recently approved a new opioid prodrug, Apadaz (benzhydrocodone and acetaminophen). The oral tablets are designed for short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Empowering Injured Workers

March 15, 2018

There’s been a lot of talk about injured worker advocacy and empowerment in workers’ compensation. But what exactly does that mean? Genex’s 2017 Heart of Case Management Award winner Lisa Armstrong, BSN, CRRN, RN-BC, has a few ideas to keep your injured workers invested in their own recovery.

New Workers' Compensation Review Contractor

March 9, 2018

Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the Medicare Set-Aside services Genex provides.

New Workers' Compensation Review Contractor

March 9, 2018

On Wednesday March 7, 2018, CMS hosted a webinar to introduce Capitol Bridge, LLC as the new contractor that will be taking over the review of MSA proposals effective March 19, 2018

StateWatch: Bill Review March 2018

March 1, 2018

Keep current with new legislation and its potential effect on your organization. This regulatory update is for informational purposes only, and provides some key highlights on state initiatives that may impact the bill review services Genex provides.

Impact of Drug Formularies on Workers' Compensation State Laws

February 28, 2018

Interest in drug formularies has grown significantly in the past few years, coinciding with a greater concern over the opioid crisis. Texas and Ohio were pioneering states in the creation of drug formularies and several states have followed suit recently. Oklahoma, Washington, Ohio, Tennessee, California, Arizona and Texas all have statewide drug formularies; states including Massachusetts, Indiana, Pennsylvania and New York are currently considering or developing formularies.